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Appropriate antibiotic dosing in critically ill, infected, patients receiving 21 
continuous renal replacement therapy (CRRT) is crucial to improve patient 22 
outcomes. Severe sepsis and septic shock result in changes in pharmacokinetic 23 
parameters, including increased volume of distribution, hypoalbuminemia and 24 
changes in renal and non-renal clearances. The lack of CRRT standardization, non-25 
recognition of how CRRT variability affects antibiotic removal, fear of antibiotic 26 
toxicity, and limited drug dosing resources all contribute to suboptimal antibiotic 27 
therapy. Even when antibiotic CRRT pharmacokinetic studies are available, they 28 
are often based on old CRRT methodologies that don’t exist in contemporary 29 
CRRT practice, resulting in unhelpful/inaccurate dosing recommendations.  30 
Application of these older doses in Monte Carlo simulation studies reveals that 31 
many of the recommended dosing regimens will never attain pharmacodynamic 32 
targets. In this review, using cefepime as an example, we illustrate whether 33 
clinicians are likely to achieve pharmacokinetic/pharmacodynamic targets when 34 
the recommended dosing regimens are prescribed in this patient population. We 35 
encourage clinicians to aggressively dose antibiotics with large loading dose and 36 
higher maintenance doses to reach the targets. 37 
=============================================== 38 
Continuous renal replacement therapy (CRRT) has been used for acute 39 
kidney injury (AKI) management in hemodynamically unstable critically ill 40 















This article is protected by copyright. All rights reserved 
effluent flow rates, all of which may profoundly affect antibiotic dosing. The wide 42 
variety of clinically used CRRT settings results in a subsequent lack of uniformity in 43 
antibiotic dosing (1).
 
Severe sepsis and septic shock are among the two most common reasons 53 
for CRRT initiation. Proper antibiotic dosing is crucial to minimize the morbidity 54 
and mortality associated with sepsis (6). Patients with sepsis or septic shock often 55 
present with a variety of physiologic abnormalities that often preclude effective 56 
antibiotic dosing. Inflammatory mediators released during the immune response 57 
result in increased capillary permeability leading to fluid accumulation and 58 
hypoalbuminemia (7). Sepsis also results in acute kidney and liver injury, however 59 
a patient with AKI may still have well-preserved non-renal (hepatic) drug 60 
clearance (5). These physiologic changes alter the pharmacokinetic parameters 61 
that must be considered for proper antibiotic dosing. 62 
Although KDIGO guidelines (2) recommend an effluent rate 44 
of 20-25 mL/kg/h for CRRT in AKI treatment, ICU physicians most commonly 45 
prescribe initial effluent flow rates that are even higher (25-35 mL/kg/h) (3). Even 46 
if the delivered CRRT dose is less than prescribed, “standard” antibiotic dosing 47 
conducted at KDIGO effluent rates is often non-therapeutic (4) and the use of 48 
even higher effluent rates would require even higher daily antibiotic doses.  The 49 
septic patient receiving CRRT desperately needs antibiotics dosed to therapeutic 50 
levels, but many barriers exist to ever achieving this goal (5). As a result, we 51 
frequently underdose antibiotics in patients on CRRT. 52 
The most important pharmacokinetic factors to consider in patients 63 
receiving CRRT are a drug’s volume of distribution, protein binding and 64 
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administration, fluid resuscitation and increased capillary permeability causes an 66 
increase in the volume of distribution of water soluble drugs. Through dilution, a 67 
reduction in antibiotic concentration in the plasma and at the site of infection will 68 
be seen. The extent of fluid overload is most prominent during the initial stages of 69 
severe sepsis but declines during the course of treatment due to the 70 
normalization of the physiologic changes and from fluid removal by CRRT (7).
 
71 
Hypoalbuminemia has been reported in 40-50% of critical care patients
 
Available clinical resources used to recommend antibiotic dosing in critically 83 
ill patients receiving CRRT often results in suboptimal therapy (4). These clinical 84 
resources that developed dosing recommendations usually were based on few 85 
pharmacokinetic studies and limited dosing information provided in package 86 
inserts. In addition, those cited studies often used conservative CRRT effluent 87 
rates and techniques that are now outdated. Interestingly, most of the studies 88 
incompletely report key pharmacokinetic information to design proper dosing 89 
(8) and 72 
can have a large effect on the amount of free (unbound) drug that has 73 
pharmacologic activity. However, the increase in free drug allows for more drug 74 
to be distributed into the interstitial space and more free drug that can be cleared 75 
by the liver, kidneys and RRT yielding a lower than expected antibiotic 76 
concentration at the site of infection. Concomitant medications, such as 77 
vasoactive agents, alter the hemodynamic state of the patient and potentially 78 
hepatic and renal drug clearance. While the potential for antibiotic toxicity should 79 
be considered, based on these pharmacokinetic changes, the prudent approach 80 
to antibiotic dosing should be an aggressive one, especially in early sepsis, to 81 
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regimens for patients receiving CRRT (9).
 
Pharmacodynamic target attainment is associated with enhanced 92 
antimicrobial activity and improved patient outcomes. Antibiotics can be divided 93 
into two different categories; concentration-dependent or time-dependent killing 94 
activity (7). The increasing antibiotic resistance in the ICU requires even more 95 
aggressive antibiotic dosing to reach pharmacodynamic goals (7). Consequently, 96 
evidence is building that older dosing recommendations do not meet the 97 
contemporary pharmacodynamic targets. Seyler et al. revealed that the 98 
recommended doses of β-lactams for patients receiving CRRT with Pseudomonas 99 
aeruginosa infection were generally not adequate to attain pharmacodynamic 100 
targets in the first 48 hours of therapy (4). Roberts et al. similarly report that usual 101 
empirical dosing of antibiotics in severely ill patients with CRRT failed to reach 102 
targets (10). The need for more aggressive antibiotic dosing in CRRT has been 103 
shown even for a very old drug that is routinely monitored, vancomycin, at 104 
effluent rates below KDIGO recommendations. In critically ill patients undergoing 105 
CVVH with ultrafiltration rates of 12-18 mL/kg/min, larger than usual vancomycin 106 
doses (500-750 mg every 12 hours) were required to attain appropriate drug 107 
exposure targets (11). The recommended antibiotic doses in these patients must 108 
be reevaluated and aggressive antibiotic dosing should be prescribed to achieve 109 
pharmacokinetic and pharmacodynamic targets.  110 
Applying these dosing recommendations 90 
to critically ill patients with modern CRRT settings must be reconsidered. 91 
How poorly do clinicians dose antibiotics in CRRT?  We can use cefepime as 111 
an example of a commonly prescribed antibiotic in this setting where we can 112 
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simulations.  Simulations using known pharmacokinetic, demographic, and CRRT 114 
data allow for experimentally “dosing” these virtual CRRT patients with cefepime 115 
to see if pharmacodynamic targets are attained.  For example, we know the 116 
weight (mean±SD kg) of the typical American ICU patient receiving RRT and the 117 
mean±SD pharmacokinetic parameters of cefepime in critical illness and its 118 
clearance by CRRT.  If we “create” 5000 virtual patients within the weight range of 119 
known CRRT patients and administer varying doses of cefepime and CRRT, we can 120 
determine the cefepime concentration-time profiles for each of these patients.  121 
By examining these profiles, we can identify whether the administered doses are 122 
likely to attain pharmacodynamic targets. 123 
 Published cefepime dosing recommendations for patients with CRRT range 124 
from 2-4 grams/day. We tested these doses using Monte Carlo simulation as 125 
described above. Patients who were the size of the typical American ICU patient 126 
receiving CVVHDF at KDIGO-effluent rates (25 mL/kg/hr) were “given” differing 127 
doses of cefepime. Optimal cefepime regimens were defined as dosing regimens 128 
that achieved >90% of probability of pharmacodynamic target attainment, 129 
defined as a plasma concentration 4 times the MIC for sensitive Pseudomonas 130 
aeruginosa of 8 mg/L (32mg/L) (12) for at least 60% of the dosing interval. The 131 
Figure illustrates that none of the published recommended cefepime regimens 132 
reached pharmacodynamic targets associated with antibiotic cure. The optimal 133 
regimen in the first 48 hours with the smallest daily dose was a loading dose of 3 134 
grams followed by a maintenance dose of 2 grams every 8 hours. This 135 
“therapeutic” dosing regimen is higher than the recommended doses for patients 136 
on CRRT and even patients with normal renal function. The need for a higher dose 137 
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unrecognized non-renal clearance and CRRT removal in critically ill patients. 139 
Validation of the results is necessary to determine antibiotic efficacy in real-life 140 
situations and prevent adverse effects from aggressive dosing. 141 
As a result of the “over-prevalent underdosing”
 
 160 
(5) of patients receiving 142 
CRRT, we must rethink the fear of antibiotic toxicity from prescribing high doses 143 
in renal impairment. The above cefepime Monte Carlo simulation demonstrates 144 
that the most common resources used to dose patients receiving CRRT result in 145 
inadequate cefepime concentrations and fail to reach established 146 
pharmacodynamic targets. If cefepime is indicative of other antibiotics also not 147 
achieving therapeutic levels in CRRT patients, and evidence suggests it is (4,10), 148 
then it should not surprise us that CRRT patients are far more likely to die of 149 
infection than any other cause (13). To ensure therapeutic doses in these 150 
complicated patients, antibiotic administration should consist of an initial loading 151 
dose and “larger than conventional” maintenance doses. Most patients in the ICU 152 
do not reach pharmacodynamic targets or experience adverse effects due to 153 
antibiotic toxicity (7), and it appears likely that we are putting patients at higher 154 
risk of infectious death with the current antibiotic dosing patterns. The evidence 155 
is increasingly compelling that in order to reduce mortality and reach 156 
pharmacokinetic-pharmacodynamic targets in this population we must reconsider 157 
the one size fits all mentality and move forward to an aggressive approach to 158 
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 163 
Figure legend Pharmacodynamic target attainment for modeled cefepime 164 
regimens in simulated patients receiving CVVHDF therapy with 25 mL/kg/h 165 
effluent flow rate for the first 48 hours of therapy 166 
 167 
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P. aeruginosa Minimum Inhibitory Concentration (mg/L) 
2g q12h 
1g q8h 
1g q 6h 
2g q8h 
4g LD, then 1 g q 6 h 
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